<DOC>
	<DOCNO>NCT00849732</DOCNO>
	<brief_summary>This three stage study evaluate safety tolerability MRKAd5 HIV-1 Gag Vaccine . In Stage I subject randomize receive vaccine 1x10^9 viral particles/dose ( vp/d ) placebo . In Stage II subject randomize receive vaccine 1x10^10 vp/d placebo . In Stage III subject randomize receive vaccine 1x10^9 vp/d , 1x10^10 vp/d , placebo . Immunogenicity single dose regimen MRKAd5 HIV-1 Gag Vaccine also measure .</brief_summary>
	<brief_title>A Worldwide , Phase I , Dose-Escalating Study 3-Dose Regimen MRKAd5 ( Clade B ) Vaccine Healthy Adults ( V520-018 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject good general health Subject test negative Hepatitis B , Hepatitis C , HIV Subjects reproductive potential agree use accept method birth control entire study Subject recent history fever time vaccination Subject receive immune globulin blood product 3 month prior injection Subject vaccinate live virus vaccine 30 day prior receipt first dose Subject vaccinate inactivated vaccine 14 day prior receipt first dose Subject chronic medical condition consider progressive Subject history malignancy Subject weigh less 105 lb . Female subject pregnant breast feeding , Male subject plan impregnate first year study Subject contraindication intramuscular injection Subject unlikely unwilling adhere low risk sex practice course study Subject tattoo deltoid region arm injection DepoProvera</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Preventive Vaccine</keyword>
</DOC>